前列腺癌组织中miRNA-34c、c-Met mRNA的表达观察

Expression of miRNA-34 and c-Met mRNA in prostate cancer tissues

目的 观察前列腺癌组织中微小RNA-34c(miR-34c)、肝细胞生长因子受体(c-Met)mRNA的表达变化,并探讨其临床意义。方法 63例前列腺癌患者,均行肿瘤切除术,术中保留癌组织;45例前列腺增生患者,留取前列腺增生组织。采用实时荧光定量PCR法检测前列腺癌组织、前列腺增生组织中miR-34c、c-MetmRNA,分析前列腺癌组织miR-34c、c-Met mRNA表达的相关性,分析miR-34c、c-Met mRNA表达与前列腺癌临床病理参数及预后的关系。结果 前列腺癌组织、前列腺增生组织中miR-34c相对表达量分别为0.521±0.426、1.247±0.681,c-Met mRNA的相对表达量分别为2.527±0.348、1.056±0.217,两者比较,P均<0.05。前列腺癌组织中miR-34c、c-Met mRNA表达呈负相关(r=-0.630,P<0.05)。miR-34c表达与前列腺癌患者Gleason评分和TNM分期有关(P均<0.05),c-MetmRNA表达与前列腺癌患者Gleason评分、TNM分期及有无远处转移有关(P均<0.05)。前列腺癌患者中miR-34c高表达者3、5年总体生存率(OS)分别为84.85%(28/33)、60.61%(22/33),miR-34c低表达者分别为70.00%(21/30)、40.00%(13/30),两者比较,P均<0.05;前列腺癌患者中c-Met mRNA高表达者3、5年OS分别为68.51%(24/35)、37.14%(13/35),c-MetmRNA低表达者分别为89.29%(25/28)、78.57%(22/28),两者比较,P均<0.05。结论 前列腺癌组织miR-34c低表达、c-MetmRNA高表达,两者可能参与前列腺癌的发生发展。

Objective To investigate the expression of miR-34c and c-Met in prostate cancer tissues, and to explore its clinical significance.Methods Sixty-three patients with prostate cancer underwent tumor resection, and the cancer tissues were preserved during operation;the prostate hyperplasia tissues from 45 patients with benign prostatic hyperplasia were collected. The real-time quantitative PCR was used to detect miR-34c and c-Met mRNA in prostate cancer tissues and benign prostatic hyperplasia tissues. The correlation of miR-34c and c-Met mRNA expression in prostate cancer tissues was analyzed, and the relationships of miR-34c and c-Met mRNA expression with the clinicopathological parameters and prognosis in patients with prostate cancer were also analyzed.Results The relative expression levels of microRNAs-34c in the prostate cancer and benign prostatic hyperplasia were 0.521±0.426 and 1.247±0.681,with statistically significant difference ( P <0.05). The relative expression of c-Met mRNA in the prostate cancer and benign prostatic hyperplasia tissues were 2.527±0.348 and 1.056±0.217,with statistically significant difference ( P <0.05). There was a negative correlation between miR-34c and c-Met mRNA expression in prostate cancer ( r =-0.630, P <0.05). The expression of microRNA-34c was correlated with Gleason score and TNM stage (both P <0.05). The expression of c-MetmRNA was correlated with Gleason score, TNM stage and distant metastasis (all P <0.05). The overall 3-year survival rate (OS) and 5-a-OS were 84.85%(28/33) and 60.61%(22/33) in patients with prostate cancer, 70.00%(21/30) and 40.00%(13/30) in patients with low expression of Mi-34c, respectively. Kaplan-Meier analysis (log-rank test) showed that 3-a-OS and 5-a-OS were significantly higher in patients with high expression of Mi-34c. The expression of 3A OS and 5A OS were 68.51%(24/35) and 37.14%(13/35) in patients with prostate cancer, 89.29%(25/28) and 78.57%(22/28) in patients with low expression of c-MetmRNA, and 89.29%(25/28) and 78.57%(22/28) in patients with low expression of c-MetmRNA, with statistically significant difference (all P <0.05).Conclusion In the prostate cancer tissues, miR-34c is low expressed and c-Met mRNA is highly expressed, both of which may be involved in the occurrence and development of prostate cancer.